Third Quarter 2026 Earnings Conference Call - CRONOS GROUP INC

Financial Performance:

• Consolidated net revenue reached $63.5 million in Q3 2026, a 75% year-over-year increase driven by cannabis flower and extract sales in Israel, Canada, and Germany.
• Gross profit totaled $32.3 million (76% YoY growth), with average sales prices rising due to a favorable geographic mix (shift to tax-advantaged markets like Israel and Europe) and higher volumes.
• Adjusted EBITDA hit a record $17.1 million, up $11.4 million YoY, supported by gross margin expansion.
• Operating expenses rose 23% YoY to $23.3 million due to increased G&A and sales/marketing spend, yet OPEX as a percentage of revenue declined from 52% to 37%.
• Balance sheet strengthened with $841 million in cash and equivalents (up $14 million QoQ), funded by $34 million operating cash flow, partially offset by $10 million CapEx and $9 million in share repurchases.
• Gross margins remain volatile quarter-to-quarter due to seasonality, product mix, and price compression; management advises analyzing trailing 12-month periods for accurate trend assessment.

Guidance and Future Outlook:

• Management projects continued organic growth in Q4 and 2027, though anticipating seasonal softness in Canadian provincial board purchases in Q4.
• International expansion outside Israel is a primary growth driver, with Germany showing robust demand despite some export permit timing lumpiness.
• The Netherlands acquisition is expected to deliver asymmetric long-term value through operational efficiencies and the potential future expansion of the current 10% population pilot program beyond its four-year term.
• Management maintains a long-term view on GroCo capacity expansions, prioritizing durable, efficient infrastructure over short-term demand fill, with no immediate plans to pull forward further expansion.
• Future profitability in new markets like the Netherlands is anticipated to improve as the company leverages borderless product formats (vapes, edibles) and operational expertise, despite near-term price compression as the market matures.

Business Segments and Product Lines:

• Israel: Achieved record net revenue for the 11th consecutive quarter, growing 33% YoY (19% constant currency), led by the "Peace Natural" brand and "Lit" value brand.
• Canada: Recorded record net revenue with 41% YoY retail sales growth vs. 1% industry growth.
  • Spinach (Vapes): Maintained #1 market position; total market share 11.4%, with "All-in-One" share at 10.2%. Launched new flavors (Strawberry Banana, Sweet Citrus, Sweet Green Apple).
  • Sours by Spinach (Edibles): Remained #1 brand (21.8% overall share, 23.6% gummies share); launched live-resin gummies and new limited editions.
  • Flour & Pre-rolls: Ranked #3 in flower (6.1% share) and #5 in pre-rolls (3.3% share), driven by tight supply and strong consumer demand.
• International (ex-Israel): Revenue surged 7x YoY to $13.2 million, led by Germany.
• Strategic Acquisition: Completed acquisition of Canadalar (largest adult-use cannabis company in Europe) in October, providing access to the Netherlands' "coffee shop" experiment market.
• Product Strategy: Aggressively introducing "borderless" derivative products (vapes, edibles) into the Netherlands where solvent-based extraction is now permitted under the pilot, leveraging existing R&D and flavor development processes.

Market and Competitive Landscape:

• Netherlands: The market is 50 years old at the consumer level but immature regarding legal supply; currently faces price compression as supply ramps up. The pilot program allows new formats (vapes/gummies) but prohibits B2B wholesale and solvent extraction.
• Competition: Spinach holds dominant positions in Canada across vapes and edibles; competitors in the Netherlands include legacy tolerated market stores and new experiment retailers.
• Market Share: Kronos is gaining share across multiple categories in Canada and expanding footprint in Germany.
• Macro Trends: Price compression is expected in all new adult-use markets as they mature; however, Kronos anticipates stability in mainstream categories where value propositions remain strong.
• Supply Constraints: Tight flower supply persists in Canada despite GroCo capacity expansions, creating a favorable pricing environment for established producers.

Risks and Challenges:

• Price Compression: Inevitable in new markets (like the Netherlands and Germany) as supply increases and market equilibrium is reached.
• Regulatory Volatility: The Netherlands market depends on the "experiment" scope; potential legislative changes or limitations on expanding the pilot to more municipalities pose risks.
• Operational Complexity: Navigating the unique Dutch regulations (no B2B wholesale, no solvent extraction currently) requires careful execution to avoid supply chain bottlenecks.
• Seasonality: Anticipated Q4 softness in Canadian government purchasing.
• Lumpiness: International revenue can be volatile quarter-to-quarter due to the timing of export permits and shipments.
• Acquisition Integration: Success in the Netherlands relies on effectively bringing derivative products to a market previously dominated by hash and pre-rolls, requiring significant capital investment in R&D and production efficiency.

Management Commentary and Tone:

• Tone was highly confident and positive, characterized by "outstanding" Q3 performance and successful execution of the "borderless" product strategy.
• Management emphasized long-term value creation over short-term gains, particularly regarding the Netherlands acquisition.
• Leaders highlighted the "asymmetric value" potential of the Canadalar deal, citing operational efficiencies and the potential for market expansion.
• CFO and CEO provided clear, data-backed explanations for financial variances, dismissing short-term volatility in favor of trailing 12-month trends.
• Strategic discipline was noted regarding capital allocation (CapEx) and distribution assets in Germany, prioritizing patient, opportunistic growth.

Analyst Questions and Answers:

• Germany Growth: Kenric Tyee (Canaccord) asked if Germany's success was demand-pull or timing; Gorenstein confirmed demand is strong but noted export timing contributes to lumpiness, advising a 12-month smoothing view.
• GroCo Expansion: Tyee inquired about accelerating capacity; Gorenstein stated they are focusing on durable, long-term efficiency rather than short-term supply fixes.
• Margin Outlook: Tyee asked about Q4/Q1 2027 margin risks; Limak reiterated reliance on trailing 12-month metrics due to quarter-to-quarter fluctuations from seasonality and mix.
• Netherlands Product Mix: Ryan Neal (TD Cowan) asked if derivative products (vapes/edibles) would displace flower in the Netherlands; Gorenstein agreed this is a reasonable expectation once regulations permit.
• Netherlands Regulations: Pablo Zenak (Zuenex) asked about the timing of pilot expansion and coffee shop license issuance; Gorenstein indicated expansion is unlikely before the 4-year term ends due to legislative hurdles, and new shop openings face long municipal approval queues.
• Competitive Advantage: Zenak asked about Kronos's cost position vs. competitors with higher-cost indoor capacity; Gorenstein confirmed Kronos's differentiated supply base and lack of B2B constraints provide a long-term upside as the company integrates its own genetics and production.
• Distribution in Germany: Zenak queried potential M&A opportunities to build Route-to-Market (RTM) via the OGI/Aurora deal; Gorenstein expressed opportunism but prioritized securing supply over immediate RTM asset acquisition.

Other Key Points:

• Market share data is sourced from HIFIRE.
• Forward-looking statements are qualified by risks detailed in SEC filings and earnings materials.
• The Netherlands "experiment" prohibits wholesale transactions between growers, meaning growers must sell directly to retailers or through a unique model, impacting the efficiency of the supply chain compared to North American markets.
• Kronos plans to pace product launches in the Netherlands to ensure proper retail messaging and avoid market flooding.
• The company holds $18 million in loans receivable and $5 million in other investments in addition to its cash position.